Lenalidomide for the treatment of relapsed multiple myeloma.
Gajraj
Elangovan
E
Chung
Helen
H
Boysen
Meindert
M
Barnett
David B
DB
Longson
Carole
C
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D015276:Health Care Rationing / Q000191:economics; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D013673:Technology Assessment, Biomedical / Q000191:economics; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide